The Bull Run 2025 has been triggered! Target $5.00 - $10.00Why I Proposed to NASDAQ:ANNX today? When will we get married?
We all know the golden rule of trading penny stocks keep emotions out of it. Let logic dictate your moves, and don’t overdo the due diligence, because today’s small-cap darling can be tomorrow’s micro-cap disaster. But today, I took a big chunk of my gains from a penny stock account and decided to put a ring on $ANNX.
This stock is like a tiny wildflower in a crowded field easy to overlook until you get up close with a magnifying glass. Let’s skip the poetry and get straight to the facts:
1. ANX005 – The Dark Horse in Neuromuscular Treatment
ANX005 is a strong contender in the treatment of Guillain-Barré Syndrome (GBS) and muscle atrophy. The drug has shown better-than-expected results in Phase 3 trials, which is huge. Institutional investors and major banks seem to have caught the scent of a potential commercial breakthrough, given how far ANX005 has progressed toward FDA approval.
2. ANX007 – A Potential Game-Changer for Vision Loss
The FDA has greenlit Phase 3 trials for ANX007, aimed at treating Geographic Atrophy (GA), a severe form of retinal degeneration. While final results are still pending, ANX007 is one of the few treatments at this advanced stage that protects and enhances vision without needing to shrink lesions. If it clears this hurdle, this could be a massive win in ophthalmology.
3. Cash Reserves > Market Cap – A Financial Fortress
Here’s where things get really interesting ANNX’s total cash reserves exceed its market cap. With only $44M in R&D costs and $9M in operational expenses, ANNX stands out among biotech penny stocks, most of which burn through cash and constantly dilute shares just to survive. Unlike them, ANNX has enough runway to last at least 8 more quarters without raising additional capital. That means no dilution risk for the next two years a rare luxury in this space.
4. Smart Clinical Trials Strategy
ANNX has prioritized international trials outside the U.S., particularly in Southwest and Southeast Asia, where costs are lower and patient enrollment is faster. While some skeptics may question data transparency, the strategy accelerates timelines and saves money. The FDA still approved ANX005 and ANX007 for their final stages, which speaks volumes about the trial results.
5. Commercial Potential – $600M Market Opportunity
The U.S. market alone could support 5,000 patients annually, translating to a potential $600M revenue stream per year. This doesn’t even factor in international markets.
Price Targets and Institutional Sentiment
Despite ANNX’s strong fundamentals, risks remain biotech investing is never smooth sailing. That said, I’m rating NASDAQ:ANNX a Moderate Buy and holding for at least 3 months, expecting a run to $4.00 –$6.00 by Q3 2025 and potentially $7.50 - 10.00 during Christmas 2025. Meanwhile, big players like:
Wells Fargo, JP Morgan, and Bank of America almost have the same consensus target of $14.
Needham says $16, HC Wainwright is going full send with $20.
Total 7 Strong Buy, 0 Hold or Sell.
Bonus Tip: Follow the Options Flow
Take a peek at NASDAQ:ANNX ’s options chain. The big dogs have been scooping up ITM and ATM call options aggressively a classic sign that they’re loading up for a serious move in the next six months.
If you’re worried about macro risks like tariffs, economic slowdowns, or financial crises, hidden gems in biotech might just be a solid "cave".
Beware short sellers, there are always sharks in the Pennystocks forums waiting for posts like this to trigger their greed. But, I bought the share by profit, target to long term, I don't mind the Daily chart, just look at Weekly and Monthly charts. Ready to DCA when ANNX drop to $1.00. Just cut loss whenever the really Bad-news is real and confirmed.
Here’s hoping my wedding day arrives when NASDAQ:ANNX hits $10.00.
(Disclaimer: ChatGPT helped me research and write this article, as Biotech is not my primary field. This is just my personal analysis. Not financial advice at all. Trade responsibly.)
